Open-Source Automated Insulin Delivery in Type 1 Diabetes

Burnside, Mercedes; Lewis, Dana; Crocket, Hamish; Meier, Renee; Williman, Jonathan; Sanders, Olivia J.; Jefferies, Craig; Faherty, Ann; Paul, Ryan; Lever, Claire; Price, Sarah Kye; Frewen, Carla; Jones, Stephanie; Gunn, Tim; Lampey, Christina; Wheeler, Benjamin J; Bock, Martin

doi:10.1056/nejmoa2203913

Cited by 84 publications

(52 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…That being said, AndroidAPS has recently been put through a randomised controlled trial. The results were recently published in the New England Journal of Medicine, 15 and are similar to those seen in the real world.…”

Section: Introductionsupporting

confidence: 79%

#We are not waiting - DIY APS Do-It-Yourself Artiﬁcial Pancreas Systems: The story so far

2022

View full text Add to dashboard Cite

Section: Introductionsupporting

confidence: 79%

#We are not waiting - DIY APS Do-It-Yourself Artiﬁcial Pancreas Systems: The story so far

2022

View full text Add to dashboard Cite

“…A recent multicentre randomised controlled parallel design study involving 97 participants (48 children aged 7 to 15 years and 49 adults) compared an open-source AID system (a modified version of AndroidAPS 2.8 with a standard OpenAPS 0.7.0 algorithm) with sensor-augmented pump therapy for six months. 17 Time in the target glucose range increased from 61±12% to 71±12% in the closed-loop group and decreased from 58±14% to 55±16% in the control group. No severe hypoglycemia or diabetic ketoacidosis occurred in either group.…”

Section: Do-it-yourself (Diy) Closed-loop Systemsmentioning

confidence: 87%

#We don't have to wait any more Closed-loop systems: transforming the landscape

Boughton

Hovorka

2022

Br J Diabetes

View full text Add to dashboard Cite

Hybrid closed-loop systems are transforming the clinical management of T1DM. Large randomised controlled trials of hybrid closed-loop systems have demonstrated safety and efﬁcacy, with signiﬁcant improvements in glycaemic control compared to control therapy, and there are now several commercially approved hybrid closed-loop systems available in the UK. There is also a growing body of evidence demonstrating the quality of life beneﬁts associated with hybrid closed-loop systems, both for users and also for parents/caregivers and other family members. We review the clinical evidence supporting currently available hybrid closed-loop systems in the UK and also new systems on the horizon. We discuss the emerging evidence for associated psychosocial beneﬁts of hybrid closed-loop therapy. We also address future challenges around healthcare professional readiness to deliver closed-loop technology and ensuring equitable access across the UK.

show abstract

“…Yet, when people with diabetes choose to use an open‐source system, a consensus statement suggests that providers should support them 209 . Recently, an RCT in those aged 7–70 years comparing use of an open‐source AID to a control group using CGM showed an increase in TIR of 10% in the AID group leading to an adjusted difference between groups of 14% 210 …”

Section: Aidmentioning

confidence: 99%

“…209 Recently, an RCT in those aged 7-70 years comparing use of an open-source AID to a control group using CGM showed an increase in TIR of 10% in the AID group leading to an adjusted difference between groups of 14%. 210…”

Section: Open-source Systemsmentioning

confidence: 99%